idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
MHH pathologist investigates how gene loss or duplication influence which organs the tumour cells migrate to.
In Germany, around 60,000 people are newly diagnosed with bowel cancer every year. The mortality rate has been falling steadily for decades. Nevertheless, colorectal cancer is one of the most common types of tumour and is responsible for around ten percent of cancer-related deaths worldwide. The tumour is particularly dangerous when it forms metastases - i.e. secondary tumours - in other organs. This occurs primarily in the liver and lungs, and more rarely in the brain. A research team led by Dr Dr Björn Sander, pathologist at the Institute of Pathology at Hannover Medical School (MHH), has investigated how genetic changes in the chromosomes, the carriers of genetic information, influence the formation of metastases and what differences exist between different types of metastases. The results of the scientific study have been published in the scientific journal ‘Nature Communications’. They could help to better assess the individual risk of metastasis formation and develop new therapeutic approaches.
Exact processes not yet well understood
Bowel cancer often develops from benign polyps in the intestinal mucosa. If these growths are not removed in time, they can grow into malignant tumours. These tumours often have complex genetic changes in their chromosomes. Certain genes are lost or duplicated, which influences the behaviour of the tumour cells. The chromosomal changes not only differ from patient to patient, but can also vary within a single tumour. Because the exact processes of metastasis formation are not yet well understood, it is particularly difficult to make prognoses or develop targeted therapies. ‘We have now examined more than 3,800 cases of colorectal cancer in detail and found that brain metastases exhibit a particularly high number of genetic changes compared to liver and lung metastases,’ says Dr Dr Sander.
Mutations in the KRAS gene promote tumour growth
The KRAS gene plays a central role in this. It carries the information for a protein that plays an important role in signalling and regulating cell growth. KRAS mutations occur particularly frequently in various types of cancer, especially lung, bowel and pancreatic cancer, and can promote the growth of tumours. In brain metastases, the researchers found a particularly frequent combination of mutations and duplications of this gene. Colonisation of the brain poses particular challenges for tumour cells. On the one hand, the cancer cells have to overcome barriers such as the blood-brain barrier, a natural barrier in the blood vessels that protects the brain from harmful substances in the bloodstream. Secondly, they have to adapt to the unique tissue environment, which is characterised by a reduced availability of oxygen for the tumour cells. "The brain itself has a high oxygen consumption. Tumour cells with detected changes in the KRAS gene show an advantage in adapting to the limited oxygen supply in the brain," explains the pathologist.
Patterns in brain metastases develop late
Another finding from the scientific study is that the diverse genetic patterns in brain metastases tend to develop late - in contrast to the less complex changes observed in liver and lung metastases. This suggests that the genetic development of the tumour cells influences in which organ the metastases form. ‘By examining samples from colorectal cancer patients who had not yet received targeted therapy, we were able to ensure that the observed genetic changes actually occur naturally and not as a result of the influence of new targeted drugs,’ says Dr Sander.
Possible weak points as an approach for new therapies
However, the results of the study not only provide insights into the mechanisms of metastasis formation, but also reveal possible weak points in the tumour cells. One approach for future therapies could be to therapeutically utilise the weak points resulting from chromosomal instability. Dr Dr Sander and his team hope that the findings will contribute to the development of personalised treatment strategies for colorectal cancer patients in the long term.
SERVICE:
The original paper ‘Cytogenetic signatures favouring metastatic organotropism in colorectal cancer’ can be found here: https://www.nature.com/articles/s41467-025-58413-1
For further information, please contact Dr Dr Björn Sander, Sander.Bjoern.PAT@mh-hannover.de.
Bowel cancer can metastasise to the liver, lungs and brain.
Copyright: pixabay, Karin Kaiser/MHH
Criteria of this press release:
Journalists
Medicine
transregional, national
Research results, Scientific Publications
English
Bowel cancer can metastasise to the liver, lungs and brain.
Copyright: pixabay, Karin Kaiser/MHH
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
